HK Stock Market Move | REMEGEN (09995) rose more than 9% during trading hours, with rapid growth in sales revenue of core products. The annual performance shows a trend of declining losses.

REMEGEN (09995) rose more than 9% during trading, and as of the time of writing, it rose by 4.87% to HK$12.92, with a turnover of HK$26.4736 million. On the news front, REMEGEN recently released its annual performance forecast. The company expects to achieve operating income of approximately RMB 1.715 billion in 2024, an increase of about 58% year-on-year; it is expected to incur a net loss attributable to shareholders of approximately RMB 1.47 billion for the period, a decrease of about 3% year-on-year. The company's core products Taixi and Vedolizumab monoclonal antibodies have seen rapid growth in sales revenue, with gross profit margins continuing to increase and selling expense ratio significantly decreasing. Therefore, although the company is expected to incur a net loss for the year 2024, overall it shows a decreasing trend in losses. In the article "Technical Signals Indicates Stock Price Rebound Imminent, How Will REMEGEN (09995) Achieve Long-term Valuation Recovery after Earnings Warning?", it points out that Taixi is expected to be approved for the indication of myasthenia gravis (MG) in China, and Vedolizumab monoclonal antibodies for HER2-positive liver metastatic breast cancer indications; at the same time, the company will submit a series of new listing applications. In addition to Taixi and Vedolizumab monoclonal antibodies, REMEGEN is accelerating the layout of anti-tumor ADC new drug products. However, from the perspective of performance-stock price catalysis, Taixi remains the main support for REMEGEN in 2025.